CLINICAL CASE STUDY: AN OVERVIEW ON LOW MOLECULAR WEIGHT HEPARINS (LMWH) IN PATIENTS

ABSTRACT

Heparin is a sulphate polysaccharide of glycosaminoglycan that is made predominantly by mast cells of connective tissue. It is used in the management of thromboembolic problems in medicine. Heparin acts as a catalyst for antithrombin III, increasing its activity by thousand times. The larger heparin species catalyses the inactivation of activated factors II and X, in contrast LMWH inactivates the activated factor X. The final effect for both is systemic anti-coagulation. Heparin also produces platelet aggregating antibodies and causes coagulopathy in rare conditions. LMWH especially Enoxaparin (Inj Clexane) proved an effective treatment in patients with Covid -19 infection by preventing thromboembolism and pulmonary embolism thereby, helped in survival of the patients by reducing the risk of death due to coagulation and fibrosis. Hence, clinical trial reports and SOAP analysis of clinical case studies in random subjects and patients reported the over-view of advantages using LMWH heparins in disease management and emergency traumatic injuries produced a beneficial role of using LMWH over unfractioned heparins.